Clinical trials: Alcoholic Liver Disease
Nonalcoholic Steatohepatitis, Liver Diseases
Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH
The purpose of this study is to explore the potential benefit of the medication, pentoxifylline, for the treatment of NASH.
- Trial name
- NCT00267670
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Northwestern University
Obesity and Type 2 Diabetes, NAFLD - Non-Alcoholic Fatty Liver Disease
OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities
The goal of this clinical trial is to learn if the use of a care model including teleconsults and the EMPOWER app can induce clinically significant weight loss and metabolic improvements in obese adults with diabetes and…
- Conditions
- Obesity and Type 2 Diabetes, NAFLD - Non-Alcoholic Fatty Liver Disease, Hypertension, Dyslipidaemia
- Trial name
- OneSTOP (NCT06890169)
- Testing
- OneSTOP program, Standard of care weight management program
- Where
- Singapore
- Volunteers
- 120 people
- Sponsor
- Changi General Hospital
Obesity, NAFLD
Effects of Two Different Exercise Programs and Diet in Obese Subjects With NAFLD
The aim of the study is to estimate the effectiveness of two different exercise programs combined with the Mediterranean diet versus diet alone on inflammatory status in subjects aged 18-65 years with obesity (BMI>30) and…
- Trial name
- Obesity_AF (NCT06186869)
- Testing
- Aerobic Exercise and diet intervention, Hiit and diet intervention, Diet
- Where
- Italy
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
NAFLD, NASH
A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH
Double-blind, randomized, placebo-controlled study to explore the efficacy and safety of elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or NASH (nonalcoholic steatohepatitis)
- Trial name
- NCT04006145
- Testing
- Elobixibat
- Where
- 10 sites in United States
- Volunteers
- 47 people
- Sponsor
- Albireo
Non-Alcoholic Fatty Liver Disease, Liver Fibrosis
Study in Healthy Adults Evaluating PF-07202954
The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a randomized, open label design, in Part 3 (if conducted).
- Trial name
- NCT04857437
- Testing
- PF-07202954 Repeat Dose, PF-07202954 Single Dose
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alcoholic Liver Disease, Non-Alcoholic Fatty Liver Disease
Integrated Approaches for Identifying Molecular Targets in Liver Disease
To provide a framework for successful clinical trials testing novel targets for therapy in liver disease. To identify molecular and cellular drivers of liver disease to provide a molecular classification and study the…
- Conditions
- Alcoholic Liver Disease, Non-Alcoholic Fatty Liver Disease, Steatohepatitis, Nonalcoholic, Steatohepatitis
- Trial name
- InLi (NCT03915002)
- Where
- United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Liver Dysfunction
Effects of Red Ginseng on Liver Function
Korea Red Ginseng (KRG) has effect on liver function
- Trial name
- NCT03945123
- Testing
- Red ginseng
- Where
- South Korea
- Volunteers
- 94 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Alcoholic Hepatitis
Changes in gUt micRobiota After Enteral Feeding (in Alcoholic Hepatitis)
Drinking large amount of alcohol can cause damage to the liver. If the liver is severely injured by alcohol it can become very inflamed and this condition is called alcoholic hepatitis.
- Trial name
- CREED (NCT04544020)
- Testing
- NG feeding
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- University of Aberdeen
Non-alcoholic Fatty Liver Disease
Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease
The purpose of this study is to evaluate the use of phlebotomy (blood taking)as a treatment for patients with non-alcoholic fatty liver disease.
- Trial name
- NCT00641524
- Testing
- Phlebotomy
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- University of Western Ontario, Canada
Steatohepatitis, Nonalcoholic
The COherence of Scatter Identification and Exclusion Algorithm Study
Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver condition worldwide; approximately 55% of the world population will have NAFLD by 2040.
- Trial name
- COSIE (NCT06975579)
- Testing
- Ultrasound image processing
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Institute of Cancer Research, United Kingdom
NAFLD, Steatosis of Liver
Response of NAFLD Patients to Mediterranean Diet
The effects of Mediterranean Diet (MedDiet) on clinical, biochemical and inflammatory profile in NAFLD patients with simple steatosis.
- Trial name
- NCT03203486
- Testing
- Mediterranean Diet
- Volunteers
- 44 people
- Sponsor
- Harokopio University
Liver Cirrhosis, Alcoholic
Feasibility of Wearable Biosensors for Monitoring Daily Activity, Heart Rate, and Sleep Among Patients With Decompensated Cirrhosis
In this protocol, the investigators will determine compliance, acceptability, and patient satisfaction regarding the use of remote monitors and summarize changes in activity over time among patients with decompensated cirrhosis.
- Trial name
- NCT06057870
- Testing
- Application on Apple watch
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Alcoholic Liver Disease
Role of CCL2 in Alcoholic Liver Diseases
Immune dysregulations, including cytokines and chemokines secretions occurs in alcoholic liver disease. Serum levels and liver expression of CCL2 are increased in patients with alcoholic hepatitis but the role of this chemokine…
- Trial name
- NCT01128010
- Volunteers
- healthy volunteers welcome
- Sponsor
- Erasme University Hospital
NAFLD, Obesity, Adolescent
Impact of Weight Loss Surgery in Adolescents With NAFLD
This study will assess the impact of weight loss surgery (WLS) on non-alcoholic fatty liver disease (NAFLD) in adolescents as well as the interaction between NAFLD and cardiometabolic risk.
- Trial name
- AWLS (NCT02952170)
- Testing
- MRI
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepatitis (NASH).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
- Trial name
- NCT05979779
- Testing
- HU6
- Where
- 20 sites in United States
- Volunteers
- 219 people
- Sponsor
- Rivus Pharmaceuticals, Inc.
MASLD, T2DM (Type 2 Diabetes Mellitus)
Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers
The goal of this observational study is to prospectively develop and validate a non-invasive scoring system based on metabolic markers, proteomic, and transcriptomic profiles to accurately screen, diagnose, stage, and monitor…
- Conditions
- MASLD, T2DM (Type 2 Diabetes Mellitus), Non-alcoholic Fatty Liver Disease (NAFLD), Obesity
- Trial name
- ENSURE-MASLD (NCT07172997)
- Testing
- Bariatric Surgery
- Where
- 2 sites in Bahrain
- Volunteers
- 163 people
- Sponsor
- Royal College of Surgeons in Ireland - Medical University of Bahrain
Non-Alcoholic Fatty Liver Disease
Dynamic Changes and Risk Factors of Fibrosis and Steatosis Progression in Nonalcoholic Fatty Liver Disease
It is an observational study of non alcoholic fatty liver disease (NAFLD) patients with a calculated sample size of 500. Liver biopsy proved NAFLD patients will be recruited in this study for 10 years follow-up.
- Trial name
- NCT03635541
- Testing
- observational group of NAFLD
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Beijing Friendship Hospital
Nonalcoholic Fatty Liver Disease, Chronic Hepatitis b
Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）
This is a prospective, multicenter, open-label, non-randomized controlled real-world study to explore the efficacy and safety and to accumulate more evidence-based medical data of an antiviral treatment programme for chronic…
- Trial name
- NCT06368882
- Testing
- Peg-Interferon α
- Where
- 5 sites in China
- Volunteers
- 1,500 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Non-alcoholic Fatty Liver Disease
Mapping of Metabolic Liver Functions in Patients With Non-alcoholic Fatty Liver Disease
Background: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the western world and an important cause of morbidity and mortality including risk of cardiovascular disease.
- Trial name
- NCT02488941
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- University of Aarhus
Non-Alcoholic Fatty Liver Disease, Gastrointestinal Microbiome
Exercise Study in Subjects With NAFLD
Non-Alcoholic Fatty Liver Disease is the most common cause of chronic liver diseases. The benign non-alcoholic fatty liver, characterized by excessive fat accumulation, can evolve into non-alcoholic steatohepatitis and liver…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Gastrointestinal Microbiome, Exercise
- Trial name
- BestTreat (NCT03995056)
- Testing
- high-intensity aerobic interval training
- Where
- Finland
- Volunteers
- 49 people
- Sponsor
- University of Eastern Finland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.